Biomarkers for early detection of colon cancer

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1118-1126

  Srivastava, S ^a   Verma, M ^a   Henson, D E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; PROTEIN P53; RAS PROTEIN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GROWTH; CARCINOMA IN SITU; COLON CANCER; EARLY DIAGNOSIS; HUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY;

ADENOMA; CHEMOPREVENTION; COLONIC NEOPLASMS; HUMANS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034906359     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (88)

1. Clonal origin of human tumors
2. Epidemiology and molecular genetics of colorectal cancer
3. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel
4. The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis
5. The molecular genetics of cancer
6. Recessive mutant genes predisposing to human cancer
7. The approaching era of the tumor suppressor genes
8. Gene losses in human tumors
9. Mutations in the p53 gene occur in diverse human tumour types
10. p53 mutations in human cancers
11. Immunohistochemical detection of ras p21 and c-myc p62 in colonic adenomas and carcinomas
12. Amplification and expression of the c-myc oncogene in human lung cancer cell lines
13. Homogeneously stained chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma
14. ras genes
15. A transforming ras gene in tumorigenic guinea pig cell lines initiated by diverse chemical carcinogens
16. Prevalence of ras gene mutations in human colorectal cancers
17. c-K-ras mutations in human carcinomas occur preferentially in codon 12
18. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer
19. Microsatellite instability in Muir-Torre syndrome
20. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
21. Identifying tumor suppressor genes in human colorectal cancer
22. Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps
23. Allelic loss at SMAD4 in polyps from juvenile polyposis patients and use of fluorescence in situ hybridization to demonstrate clonal origin of the epithelium
24. The use of biomarker expression to characterize neoplastic processes
25. The use of biomarker expression in the development of prostatic adenocarcinoma
26. Serum C-peptide insulin-like growth factor I, IGF-binding proteins, and colorectal risk in women
27. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer
28. Nonsteroidal anti-inflammatory drugs and cancer prevention
29. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers
30. Identification and characterization of the familial adenomatous polyposis coli gene
31. A genetic model for colorectal tumorigenesis
32. Genomic rearrangements of the APC tumor-suppressor gene in familial adenomatous polyposis
33. A follow-up study of colonic epithelial proliferation as a biomarker in a Native American family with hereditary nonpolyposis colon cancer
34. Etiology, natural history, management and molecular genetics of hereditary nonpolyposis colorectal cancer (Lynch syndromes): Genetic counseling implications
35. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women
36. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors
37. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients
38. Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay
39. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
40. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome
41. A germ line mutation in exon 5 of the p53 gene in an extended cancer family
42. Met/HGF receptor modulates bcl-2 expression and inhibits apoptosis in human colorectal cancers
43. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
44. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer
45. Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers
46. pp60c-src activation in human colon carcinoma
47. Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA)
48. 111In-CYT-103, in the management of colon cancer
49. Constitutive transcriptional activation by β catenin-Tef complex in APC-/- colon carcinoma
50. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC
51. β-catenin regulates expression of cyclin D1 in colon carcinoma cells
52. Frequent mutation of β-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer
53. Bcl-2 expression in human colorectal adenomas and carcinomas
54. Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas
55. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis
56. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenocarcinomas and carcinomas
57. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas
58. Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia
59. Immunohistochemically detectable Bcl-2 expression in colorectal carcinoma: Correlation with tumor stage and patient survival
60. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma
61. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma
62. Colorectal cancer and noncancer patients have similar labeling indices by microscopy and computed image analysis
63. Individuals with a strong family history of colorectal cancer demonstrate abnormal rectal mucosal proliferation
64. Proliferative patterns in colonic mucosa in familial polyposis
65. Proliferation in human gastrointestinal epithelium using bromodeoxyuridine in vivo: Data for different sites, proximity to a tumor, and polyposis coli
66. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II. Biomarker studies
67. Failure to detect colonic mucosal hyperproliferation in mutation positive members of a family with hereditary non-polyposis colorectal cancer
68. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis
69. The prad-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas
70. Different expression patterns of cyclins A, D1 and E in human colorectal cancer
71. Expression of cyclin E in colorectal adenomas and adenocarcinomas: Correlation with expression of Ki67 antigen and p53 protein
72. Concurrent amplification of cyclin E and cdk2 genes in colorectal carcinomas
73. Detection of colorectal polyps by computed tomographic colography: Feasibility of a novel technique
74. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
75. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: Comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer
76. Colon cancer: A role for cyclooxygenase-2-specific nonsteroidal anti-inflammatory drugs
77. Aspirin use and reduced risk of fatal colon cancer
78. Aspirin use and risk of fatal cancer
79. Incidence of cancer among patients with rheumatoid arthritis
80. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
81. Low-dose aspirin and incidence of colorectal tumors in a randomized trial
82. Prospects for preventing colorectal cancer death
83. Aspirin and the prevention of colorectal cancer: A review of the evidence
84. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
85. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
86. Inhibition of prostaglandin synthesis: Potential for chemoprevention of human colon cancer
87. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer